Technology ID
TAB-3752
Methods For Pharmacologic Treatment of Stroke
E-Numbers
E-112-2018-0
Lead Inventor
Jacobson, Kenneth (NIDDK)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Neurology
Lead IC
NIDDK
ICs
NIDDK
This technology includes P2X4R adenosine receptor antagonists, including NP-1815-PX and 5-BDBD, for treating stroke. Stroke is the fifth leading cause of death for Americans and a leading cause of serious long-term disability. Current approaches to treating ischemic stroke are primarily limited to the administration of thrombolytic therapeutics such as tissue plasminogen activator, or to an invasive endovascular procedure involving the use of a clot removing/retrieving device. Thrombolytic therapeutics, however, must be given during the first few hours of a stroke, are associated with a risk of bleeding, and are only useful for ischemic strokes, not for hemorrhagic strokes. The clot removing/retrieving device is applicable in less than 10% of embolic stroke cases. Thus, improved medical therapy for stroke, particularly ischemic stroke, is needed and represents an unmet area of need.
Commercial Applications
Treatment for stroke.
Competitive Advantages
Focuses on unmet medical need.
Licensing Contact: